All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
On Sunday 3rd June an oral abstract session took place at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract 7500 was presented by Nathan Fowler, The University of Texas MD Anderson Cancer Center, Texas, on the RELEVANCE study.
The randomized, phase III study looked at the combination of lenalidomide plus rituximab (R2) compared with chemotherapy with rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma (FL).
In the first 6 months, patients were treated with either 20mg per day (Day2-22/28) and rituximab 375 mg/m2 or investigator/patient choice chemotherapy (R-CHOP 72%, R-B 23% and R-CVP 5%). Both treatment arms would then continue on to rituximab maintenance after 6 months up to a year. The co-primary endpoint was complete remission (CR) or CRu at 120 weeks.
Dr Fowler concluded his talk stating that the R2 regimen was not superior to R-chemo based on the interim PFS analysis at 120 weeks and that the efficacy results were similar. The study is ongoing for continued follow-up of mature PFS and OS results.
Lymphoma Hub Satellite Symposium 2019 | Chemo-free approaches for the treatment of lymphoid malignancies - Professor Nathan Fowler
Professor Nathan Fowler, University of Texas MD Anderson Cancer Centre, Houston, US, presented the current state of...
Bruce Cheson | ASCO 2018 | Potential for chemotherapy-free future in lymphoid malignancies
Bruce Cheson | ASCO 18 | Potential for chemotherapy-free future in lymphoid malignancies
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox